Latest news

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and...

We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1...

We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close...

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of...

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data....

Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to...

Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg /...

Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection...

Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of...

Adalvo is pleased to announce that following the successful compilation of all necessary requirements, we have submitted our dossier for Enzalutamide, and did proceed for filing via several DCP procedures...

Adalvo is pleased to announce that in light of the most recent General Court decision that revoked data exclusivity protection on Dimethyl Fumarate (Tecfidera®) hard capsules, we have submitted our...

Adalvo is very excited about this unique opportunity with vast orphan market potential

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine hard capsules development which demonstrates Adalvo´s ability to continuously offer first-to-market opportunities to its valued partners.

Adalvo is happy to announce that following the successful compilation of all necessary requirements today we submitted our Solifenacin+Tamsulosin MR Tablet dossier and will proceed via several DCP procedures in...

Here at Adalvo we are committed to being always on target with the aim of achieving great results for our partners and patients.

Adalvo is delighted to announce the completion of an eCTD format dossier on our Pomalidomide hard capsules development.

Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.

We are happy to announce a positive pivotal PK outcome of our Drospirenone + Estradiol development which is our new milestone in creating Adalvo’s mission for a boutique portfolio containing...

As the Holidays are rapidly approaching, we really wanted to take this opportunity to thank you all for your wonderful collaboration and support in what has undoubtedly been a truly...